VK-2735 is under clinical development by Viking Therapeutics and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VK-2735’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VK-2735 overview
Viking Therapeutics overview
Viking Therapeutics is a clinical-stage biopharmaceutical company that primarily focuses on the development of novel therapies for metabolic and endocrine disorders. It offers products in clinical trials that include VK2809, VK2735, and VK0214, that are designed to treat lipid and metabolic disorders, obesity, and X-linked adrenoleukodystrophy (X-ALD) respectively. Viking Therapeutics operates primarily in the biopharmaceutical industry, focusing on metabolic and endocrine disorders. The company’s target market includes patients suffering from these disorders, with a particular emphasis on those with non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), obesity, and X-ALD. Viking Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of VK-2735’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
